Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 2/20 | 0.54 |
| ▸ | RXRB | P28702 | 2/20 | 0.54 |
| ▸ | RXRG | P48443 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4825655 | 1.00 | RXRA (0.54) | RXRARXRBRXRGSMN1; SMN2GAA | |
| SCHEMBL5693704 | 0.81 | RXRA (0.55) | RXRARXRBRXRGSMN1; SMN2GAA | |
| SCHEMBL5693706 | 0.81 | RXRA (0.55) | RXRARXRBRXRGSMN1; SMN2GAA | |
| SCHEMBL4830848 | 0.81 | NR1H4 (0.48) | RXRARXRBRXRGSMN1; SMN2NR1H4 | |
| SCHEMBL4830858 | 0.81 | NR1H4 (0.48) | RXRARXRBRXRGSMN1; SMN2NR1H4 | |
| SCHEMBL337560 | 0.78 | MRGPRX4 (0.58) | RXRARXRBRXRGSMN1; SMN2GAA | |
| SCHEMBL4826453 | 0.75 | XDH (0.46) | RXRARXRBKDM4ENPC1RAB9A | |
| SCHEMBL4826442 | 0.75 | XDH (0.46) | RXRARXRBKDM4ENPC1RAB9A | |
| SCHEMBL13125267 | 0.74 | MRGPRX4 (0.54) | RXRARXRBRXRGSMN1; SMN2GAA | |
| SCHEMBL177169 | 0.72 | THRA (0.56) | SMN1; SMN2GAAMRGPRX4NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7420083-B2 | Substituted aryloximes | WYETH (US) | 2008-09-02 | — | — | US | claimed |
| EP-1663189-A1 | 4-(PHENYL-ETHYLIDENEAMINOXY-PROPOXY)-PHENYL-ACETIC ACID DERIVATIVES AND RELATED COMPOUNDS AS PAI-1 INHIBITORS FOR THE TREATMENT OF IMPAIREMENT OF THE FIBRINOLYTIC SYSTEM AND OF THROMBISIS | Wyeth (US) | 2006-06-07 | — | — | EP | claimed |
| WO-2005030193-A1 | 4-(PHENYL-ETHYLIDENEAMINOXY-PROPOXY) -PHENYL-ACETIC ACID DERIVATIVES AND RELATED COMPOUNDS AS PAI-1 INHIBITORS FOR THE TREATMENT OF IMPAIRMENT OF THE FIBRINOLYTIC SYSTEM AND OF THROMBOSIS | WYETH (US) | 2005-04-07 | — | — | WO | claimed |
| US-20050070584-A1 | Substituted aryloximes | WYETH (US) | 2005-03-31 | — | — | US | claimed |
| US-20080293790-A1 | SUBSTITUTED ARYL OXIMES | WYETH (US) | 2008-11-27 | — | — | US | disclosed |
| US-7420083-B2 | Substituted aryloximes | WYETH (US) | 2008-09-02 | — | — | US | disclosed |
| EP-1663189-A1 | 4-(PHENYL-ETHYLIDENEAMINOXY-PROPOXY)-PHENYL-ACETIC ACID DERIVATIVES AND RELATED COMPOUNDS AS PAI-1 INHIBITORS FOR THE TREATMENT OF IMPAIREMENT OF THE FIBRINOLYTIC SYSTEM AND OF THROMBISIS | Wyeth (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005030193-A1 | 4-(PHENYL-ETHYLIDENEAMINOXY-PROPOXY) -PHENYL-ACETIC ACID DERIVATIVES AND RELATED COMPOUNDS AS PAI-1 INHIBITORS FOR THE TREATMENT OF IMPAIRMENT OF THE FIBRINOLYTIC SYSTEM AND OF THROMBOSIS | WYETH (US) | 2005-04-07 | — | — | WO | disclosed |
| US-20050070584-A1 | Substituted aryloximes | WYETH (US) | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070584-A1 | Substituted aryloximes | AHR, NQO1, AOX1 | RXRA 1225/4885RXRB 893/4885RXRG 1295/4885 |
| US-20080293790-A1 | SUBSTITUTED ARYL OXIMES | HCCS, AOX1, TET2 | RXRA 587/4885RXRB 493/4885RXRG 692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.